Physician profile
Ryan Volking
NPI 1538671748
$14,496.63
in general payments reported to CMS, 2019-2025
28 companies · $3,827 in 2025
The $3,827 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,822 · 2022: $2,812 · 2023: $3,172 · 2024: $2,863 · 2025: $3,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,377 · Consulting Fee: $1,125 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,377.35 |
| Consulting Fee | $1,125.00 |
| Education | $359.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $3,200.80 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $2,611.62 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,649.55 | 2021-2025 | |
| Genzyme Corporation | $978.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $948.01 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $784.07 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $702.24 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $542.43 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $459.84 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $446.97 | 2021-2025 | Opzelura |
| Ucb, INC. | $403.55 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $369.39 | 2021-2024 | |
| Amgen INC. | $240.03 | 2021-2025 | Enbrel, Otezla, Otezla |
| Leo Pharma INC. | $226.13 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $162.13 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $139.36 | 2021-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $119.76 | 2021-2024 | |
| Mimedx Group, INC. | $105.95 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.70 | 2023-2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $72.56 | 2024-2025 | Zoryve |
| Almirall LLC | $68.14 | 2022-2025 | Seysara |
| Botanix Sb INC | $50.35 | 2025 | Sofdra |
| Organon LLC | $45.65 | 2025 | Vtama |
| Dermira, INC. | $21.28 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.98 | 2024 | Jublia, Arazlo |
| Kerecis Limited | $19.14 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $17.17 | 2025 | Nuzyra |
| Epi Health, LLC | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Volking listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.